Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abelacimab versus enoxaparin after elective unilateral total knee arthroplasty
2019-003756-37Phase 2Completed
- Sponsor
- Anthos Therapeutics
- Start
- Feb 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in venous thromboembolism (VTE) comparing Abelacimab dose-ranging arm(s) with Enoxaparin active control (2 arms). Primary endpoint: Composite venous thromboembolism endpoint through Day 10. Started Feb 2020; status: completed.
02
Drugs
abelacimabenoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2019-003756-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003756-37.